Definitive Contract 75N91019C00047
Award Date
9/16/19
Potential Completion Date
6/25/24
Potential Value
$299K
Federal Agency
National Cancer Institute
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Baltimore, MD 21231, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Radiopharmaceutical Imaging And Dosimetry, LLC (doing business as Radiopharmaceutical Imaging & Dosimetry LLC), a for-profit limited liability company. The $299,466.00 firm-fixed-price contract, which was set aside for small businesses, is for the development of user-friendly, platform-independent software to incorporate...
This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Neuralrad LLC, a small business, for $454,559.00. The contract was awarded under the SBIR (Small Business Innovation Research) program to support the development of "Quantitative Imaging Software Tools for Cancer Diagnosis and Treatment Planning" as described in the original solicitation. This Phase I SBIR contract has a period of performance from...
This is a definitive, firm-fixed price contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute to Radiopharmaceutical Imaging And Dosimetry, LLC, doing business as Radiopharmaceutical Imaging & Dosimetry LLC, a small business. The $1,999,796.00 contract is for treatment optimization services by combining alpha-emitter therapy (ARPT) and radiotherapy (XRT) dosimetry for prostate cancer patients. Radiopharmaceutical...
This is a $300,000.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Icagen, Inc. for a Small Business Innovation Research (SBIR) Phase I project titled "SYSTEMIC TARGETED RADIONUCLIDE THERAPY FOR CANCER TREATMENT". The period of performance is from September 22, 2015 to June 21, 2016, with an ultimate completion date of September 30, 2016. This contract was not set aside for a specific business size or type. The goal of this SBIR...
This $2,399,183 firm-fixed-price SBIR Phase I contract was awarded by the National Cancer Institute (NCI) to Radiologics, Inc., a small business, to conduct research and development on cancer imaging tools and image de-identification software. The contract is part of the NCI's SBIR program, which aims to stimulate technological innovation and increase private sector commercialization of innovations derived from federal R&D. The contract has a period of performance through January 2024 and is...
<p>This is a $298,934 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Houston Pharmaceutical Inc., a small business. The contract is for a Small Business Innovation Research (SBIR) Phase I project to develop a Targeted Radionuclide Therapy for Pancreatic Cancer. The contract has a period of performance through December 31, 2017. This award represents a set-aside for small businesses.</p>
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institutes of Health (NIH) National Cancer Institute to Radiologics, Inc., a for-profit organization. The contract, valued at $225,000.00, is for the development of FDA-compliant imaging informatics for cancer research under SBIR Topic 365. As a SBIR Phase I award, this contract is set aside for small businesses. The contract has a firm fixed price pricing type and was awarded on September 18, 2017, with...
This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services' National Institutes of Health, to Radiomedix, Inc., a small disadvantaged business. The contract, valued at $1,994,002.00, is for the development of targeted radionuclide therapy using 212Pb-octreotate analogs for the treatment of neuroendocrine tumors. The contract was awarded on September 18, 2018 and has a completion date of...
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
This contract was awarded by the National Cancer Institute, a civilian agency, to Radiomedix, Inc., a small disadvantaged business, for the Targeted Radionuclide Therapy of Neuroendocrine Tumors Using Pb212-Octreotate Analogs project. The contract has a ceiling value of $298,132.00 and was awarded under the Small Business Innovation Research (SBIR) Program Phase I. The contract is a Definitive Contract with a Firm Fixed Price pricing type and has an ultimate completion date of August 18, 2017.